Skip to main content

Table 3 Meta-regression

From: Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis

 

OR rate

CR rate

RR

Study (n)

R2 (%)

p-value

Study (n)

R2 (%)

P-value

Study (n)

R2 (%)

p-value

Sample size

37

5.11

0.1079

37

1.29

0.2262

32

0.00

0.7044

Year of publication

37

0.00

0.3522

37

5.83

0.0905

32

0.00

0.9247

Age

30

23.29

0.0103

30

45.37

< 0.0001

27

0.00

0.3689

Proportion of male

30

0.00

0.6095

30

0.00

0.5294

27

0.00

0.4814

Evaluation time

29

3.70

0.2370

29

0.00

0.4967

27

0.00

0.6003

Follow-up time

37

8.59

0.1167

37

0.00

0.9396

32

0.00

0.6639

Quality score

37

0.00

0.1886

37

0.10

0.3369

32

0.42

0.3695